CHENGDU, China, Nov. 6 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., , a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced the appointment of Mr. Tao Yang to the position of Chief Advisor of Sales and Marketing Strategy Committee and special advisor to its CEO to assist optimizing the Company's distribution network and building a staff training system.
Mr. Yang is a well-known certified training specialist with more than 18 years experience in sales and marketing industry. He started his career as a salesman, marketing manager and a training specialist at Astra Zeneca of Sweden and Bayer of Germany, respectively since 1991. Meanwhile, he also received systematic training in the US from Learning International, DDI, AMI, Train the Trainer and later became its certified training specialist. He has been an advisor and training specialist for more than 85 domestic and international enterprises since 1998 including many pharmaceutical companies such as Grunenthal- San Huan Pharmaceutical (China) Co., Ltd., Beaufour Ipsen Pharmaceutical Co., Ltd., and Yangtze River Pharmacy Group, etc. Mr. Yang also served as BPIP implementation consultant of CPDF launched by World Bank since 2001, and the executive advisor of a policy system program in 2007, which is a training system formed by the Chinese and British government aiming to support the domestic small to medium size businesses.
Dr. Jiang Guoqing, Tianyin's Chairman and Chief Executive Officer, said, "We are very pleased to have Mr. Yang join as our Chief Advisor of Sales and Marketing Strategy Committee and as my special advisor. As we continue to strengthen our sales and marketing effort, Mr. Yang's experience will further improve our distribution network as well as build a strong sales and marketing team. We are confident that the new appointment will help create a stronger organization and help facilitate our future growth."
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 33 modernized TCMs and 5 generic western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 47 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin, please visit http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
CONTACT: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO,
China, +86-158-2122-5642, or Allen.y.tang@gmail.com; Investors: Alan
Sheinwald of HC International, Inc., US, +1-914-669-0222, or
Alan.Sheinwald@hcinternational.net
Web site: http://www.tianyinpharma.com/
